Table 3. Characteristics of patients with clinical benefit rate (PR + SD > 6months).
| Pt | Age/Gender | Diagnosis | Phase I Regimen(s) | Best response | PFS on Phase I trial (months) |
|---|---|---|---|---|---|
| 1 | 57/F | Intrahepatic CC | HAI Oxaliplatin + IV Bevacizumab + IV 5FU | PR on Phase I, NED post resection** | 16.7 |
| 22 | 55/M | Intrahepatic CC | HAI Oxaliplatin + IV 5FU + IV Bevacizumab + IV Cetuximab | PR | 9+ |
| 34 | 47/F | Intrahepatic CC | HAI Nab-Paclitaxel + IV Gemcitabine + IV Bevacizumab | PR | 7.1+ |
| 8 | 55/F | Intrahepatic CC | HAI Oxaliplatin + IV Bevacizumab + IV 5FU | SD | 6.4 |
| 37 | 69/F | Intrahepatic CC | HAI Oxaliplatin + IV Bevacizumab + IV 5FU | SD | 7.2 |
| 26 | 71/F | Extrahepatic CC | HAI Nab-Paclitaxel | SD | 7.4 |
| 36 | 61/F | Gallbladder carcinoma | Bevacizumab + Trastuzumab + Lapatinib; Trastuzumab + Erlotinib | SD | 10.4 |
| 25 | 47/M | Intrahepatic CC | Bevacizumab + Sorafenib | SD | 10.9 |
| 39 | 67/M | Intrahepatic CC | HAI Oxaliplatin + IV Bevacizumab + IV 5FU | SD | 11.3 |
| 38 | 60/F | Intrahepatic CC | Bevacizumab + Sorafenib; Sirolimus + Cetuximab | SD | 14.3 |
| 15 | 53/M | Intrahepatic CC | Novel MEK inhibitor | SD | 8.9 |
5-FU fluorouracil; CC cholangiocarcinoma; CR complete response; HAI hepatic arterial infusion; PR partial response; SD stable disease
**
This patient went on to receive neoadjuvant bevacizumab + proton therapy, followed by an extended hepatectomy, ultimately showing no evidence of disease (NED).